Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeRx-521
- Development stage
- Preclinical
- Lead developer
- Gelteq
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
GeRx-521 is a preclinical-stage oral gel formulation being developed by Gelteq for the treatment of allergies in animals. Utilizing Gelteq's proprietary gel-based drug delivery platform, the formulation is designed to improve palatability, ease of administration, and dosage control in veterinary medicine.
Beyond the preview
Go deeper on GeRx-521.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeRx-521.